Journal of Osteoporosis最新文献_第7页

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. 治疗骨质疏松症的硬骨蛋白抗体疗法：临床前景与挑战。

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-01 Epub Date: 2016-05-26 DOI: 10.1155/2016/6217286

Claire MacNabb, D Patton, J S Hayes

{"title":"Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges.","authors":"Claire MacNabb, D Patton, J S Hayes","doi":"10.1155/2016/6217286","DOIUrl":"10.1155/2016/6217286","url":null,"abstract":"It is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment. Existing therapeutic treatments for osteoporosis are associated with a variety of issues relating to use, clinical predictability, and health risks. Consequently, additional novel therapeutic targets are increasingly sought. A promising therapeutic candidate is sclerostin, a Wnt pathway antagonist and, as such, a negative regulator of bone formation. Sclerostin antibody treatment has demonstrated efficacy and superiority compared to other anabolic treatments for increasing bone formation in both preclinical and clinical settings. Accordingly, it has been suggested that sclerostin antibody treatment is set to achieve market approval by 2017 and aggressively compete as the gold standard for osteoporotic treatment by 2021. In anticipation of phase III trial results which may potentially signify a significant step in achieving market approval here, we review the preclinical and clinical emergence of sclerostin antibody therapies for both osteoporosis and alternative applications. Potential clinical challenges are also explored as well as ongoing developments that may impact on the eventual clinical application of sclerostin antibodies as an effective treatment of osteoporosis. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2016 ","pages":"6217286"},"PeriodicalIF":1.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34650746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy. 银屑病患者骨小梁评分与炎症和肥胖的关系:阿达木单抗治疗的效果。

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-01 Epub Date: 2016-05-12 DOI: 10.1155/2016/5747852

José L Hernández, Raquel López-Mejías, Ricardo Blanco, Trinitario Pina, Sheila Ruiz, Isabel Sierra, Begoña Ubilla, Verónica Mijares, Marcos A González-López, Susana Armesto, Alfonso Corrales, Enar Pons, Patricia Fuentevilla, Carmen González-Vela, Miguel Á González-Gay

{"title":"Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy.","authors":"José L Hernández, Raquel López-Mejías, Ricardo Blanco, Trinitario Pina, Sheila Ruiz, Isabel Sierra, Begoña Ubilla, Verónica Mijares, Marcos A González-López, Susana Armesto, Alfonso Corrales, Enar Pons, Patricia Fuentevilla, Carmen González-Vela, Miguel Á González-Gay","doi":"10.1155/2016/5747852","DOIUrl":"https://doi.org/10.1155/2016/5747852","url":null,"abstract":"Studies on trabecular bone score (TBS) in psoriasis are lacking. We aim to assess the association between TBS and inflammation, metabolic syndrome features, and serum adipokines in 29 nondiabetic patients with psoriasis without arthritis, before and after 6-month adalimumab therapy. For that purpose, adjusted partial correlations and stepwise multivariable linear regression analysis were performed. No correlation was found between TBS and disease severity. TBS was negatively associated with weight, BMI, waist perimeter, fat percentage, and systolic and diastolic blood pressure before and after adalimumab. After 6 months of therapy, a negative correlation between TBS and insulin resistance (p = 0.02) and leptin (p = 0.01) and a positive correlation with adiponectin were found (p = 0.01). The best set of predictors for TBS values at baseline were female sex (p = 0.015), age (p = 0.05), and BMI (p = 0.001). The best set of predictors for TBS following 6 months of biologic therapy were age (p = 0.001), BMI (p < 0.0001), and serum adiponectin levels (p = 0.027). In conclusion, in nondiabetic patients with moderate-to-severe psoriasis, TBS correlates with metabolic syndrome features and inflammation. This association is still present after 6 months of adalimumab therapy. Moreover, serum adiponectin levels seem to be an independent variable related to TBS values, after adalimumab therapy. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2016 ","pages":"5747852"},"PeriodicalIF":1.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/5747852","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34473662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Cross-Calibration of GE Healthcare Lunar Prodigy and iDXA Dual-Energy X-Ray Densitometers for Bone Mineral Measurements. 用于骨矿物质测量的GE医疗保健Lunar Prodigy和iDXA双能x射线密度仪的交叉校准。

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-01 Epub Date: 2016-04-27 DOI: 10.1155/2016/1424582

J Saarelainen, M Hakulinen, T Rikkonen, H Kröger, M Tuppurainen, H Koivumaa-Honkanen, R Honkanen, M Hujo, J S Jurvelin

{"title":"Cross-Calibration of GE Healthcare Lunar Prodigy and iDXA Dual-Energy X-Ray Densitometers for Bone Mineral Measurements.","authors":"J Saarelainen, M Hakulinen, T Rikkonen, H Kröger, M Tuppurainen, H Koivumaa-Honkanen, R Honkanen, M Hujo, J S Jurvelin","doi":"10.1155/2016/1424582","DOIUrl":"https://doi.org/10.1155/2016/1424582","url":null,"abstract":"In long-term prospective studies, dual-energy X-ray absorptiometry (DXA) devices need to be inevitably changed. It is essential to assess whether systematic differences will exist between measurements with the new and old device. A group of female volunteers (21-72 years) underwent anteroposterior lumbar spine L2-L4 (n = 72), proximal femur (n = 72), and total body (n = 62) measurements with the Prodigy and the iDXA scanners at the same visit. The bone mineral density (BMD) measurements with these two scanners showed a high linear association at all tested sites (r = 0.962-0.995; p < 0.0001). The average iDXA BMD values were 1.5%, 0.5%, and 0.9% higher than those of Prodigy for lumbar spine (L2-L4) (p < 0.0001), femoral neck (p = 0.048), and total hip (p < 0.0001), respectively. Total body BMD values measured with the iDXA were -1.3% lower (p < 0.0001) than those measured with the Prodigy. For total body, lumbar spine, and femoral neck, the BMD differences as measured with these two devices were independent of subject height and weight. Linear correction equations were developed to ensure comparability of BMD measurements obtained with both DXA scanners. Importantly, use of equations from previous studies would have increased the discrepancy between these particular DXA scanners, especially at hip and at spine. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2016 ","pages":"1424582"},"PeriodicalIF":1.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/1424582","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34425167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective Denosumab用于老年男性骨质疏松症:从美国付款人的角度进行成本-效果分析

IF 1.9

Journal of Osteoporosis Pub Date : 2015-12-09 DOI: 10.1155/2015/627631

S. Silverman, I. Agodoa, M. Kruse, A. Parthan, E. Orwoll

{"title":"Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective","authors":"S. Silverman, I. Agodoa, M. Kruse, A. Parthan, E. Orwoll","doi":"10.1155/2015/627631","DOIUrl":"https://doi.org/10.1155/2015/627631","url":null,"abstract":"Purpose. To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective. Methods. A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used. Men in the model were 78 years old, with a BMD T-score of −2.12 and a vertebral fracture prevalence of 23%. During each 6-month Markov cycle, patients could have experienced a hip, vertebral or nonhip, nonvertebral (NHNV) osteoporotic fracture, remained in a nonfracture state, remained in a postfracture state, or died. Background fracture risks, mortality rates, persistence rates, health utilities, and medical and drug costs were derived from published sources. Previous PMO studies were used for drug efficacy in reducing fracture risk. Lifetime expected costs and quality-adjusted life-years (QALYs) were estimated for denosumab, generic alendronate, risedronate, ibandronate, teriparatide, and zoledronate. Results. Denosumab had an incremental cost-effectiveness ratio (ICER) of $16,888 compared to generic alendronate and dominated all other treatments. Results were most sensitive to changes in costs of denosumab and the relative risk of hip fracture. Conclusion. Despite a higher annual treatment cost compared to other medications, denosumab is cost-effective compared to other osteoporotic treatments in older osteoporotic US men.","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"1 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2015-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89659332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women. 绝经后晚期骨质疏松症妇女外周血中存活相关基因的上调和哺乳动物雷帕霉素靶蛋白及成骨细胞分化相关基因的下调与骨质流失的关系

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-02-10 DOI: 10.1155/2015/802694

Elena V Tchetina, Karina A Maslova, Mikhail Y Krylov, Valery A Myakotkin

{"title":"Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women.","authors":"Elena V Tchetina, Karina A Maslova, Mikhail Y Krylov, Valery A Myakotkin","doi":"10.1155/2015/802694","DOIUrl":"https://doi.org/10.1155/2015/802694","url":null,"abstract":"We aimed to identify bone related markers in the peripheral blood of osteoporotic (OP) patients that pointed toward molecular mechanisms underlying late postmenopausal bone loss. Whole blood from 22 late postmenopausal OP patients and 26 healthy subjects was examined. Bone mineral density (BMD) was measured by DXA. Protein levels of p70-S6K, p21, MMP-9, TGFβ1, and caspase-3 were quantified by ELISA. Gene expression was measured using real-time RT-PCR. OP registered by low BMD indices in late postmenopausal patients was associated with a significant upregulation of autophagy protein ULK1, cyclin-dependent kinase inhibitor p21, and metalloproteinase MMP-9 gene expression in the blood compared to the healthy controls and in a significant downregulation of mTOR (mammalian target of rapamycin), RUNX2, and ALPL gene expression, while expression of cathepsin K, caspase-3, transforming growth factor (TGF) β1, interleukin- (IL-) 1β, and tumor necrosis factor α (TNFα) was not significantly affected. We also observed a positive correlation between TGFβ1 and RUNX2 expression and BMD at femoral sites in these patients. Therefore, bone loss in late postmenopausal OP patients is associated with a significant upregulation of survival-related genes (ULK1 and p21) and MMP-9, as well as the downregulation of mTOR and osteoblast differentiation-related genes (RUNX2 and ALPL) in the peripheral blood compared to the healthy controls. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"802694"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/802694","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33120872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Whole-Body Electromyostimulation to Fight Osteopenia in Elderly Females: The Randomized Controlled Training and Electrostimulation Trial (TEST-III). 全身肌电刺激对抗老年女性骨质减少:随机对照训练和电刺激试验(TEST-III)。

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-02-15 DOI: 10.1155/2015/643520

Simon von Stengel, Michael Bebenek, Klaus Engelke, Wolfgang Kemmler

{"title":"Whole-Body Electromyostimulation to Fight Osteopenia in Elderly Females: The Randomized Controlled Training and Electrostimulation Trial (TEST-III).","authors":"Simon von Stengel, Michael Bebenek, Klaus Engelke, Wolfgang Kemmler","doi":"10.1155/2015/643520","DOIUrl":"https://doi.org/10.1155/2015/643520","url":null,"abstract":"Whole-body electromyostimulation (WB-EMS) has been shown to be effective in increasing muscle strength and mass in elderly women. Because of the interaction of muscles and bones, these adaptions might be related to changes in bone parameters. 76 community-living osteopenic women 70 years and older were randomly assigned to either a WB-EMS group (n = 38) or a control group (CG: n = 38). The WB-EMS group performed 3 sessions every 14 days for one year while the CG performed gymnastics containing identical exercises without EMS. Primary study endpoints were bone mineral density (BMD) at lumbar spine (LS) and total hip (thip) as assessed by DXA. After 54 weeks of intervention, borderline nonsignificant intergroup differences were determined for LS-BMD (WB-EMS: 0.6 ± 2.5% versus CG -0.7 ± 2.5%, P = .051) but not for thip-BMD (WB-EMS: -1.1 ± 1.9% versus CG: -0.8 ± 2.3%, P = .771). With respect to secondary endpoints, there was a gain in lean body mass (LBM) of 1.5% (P = .006) and an increase in grip strength of 8.4% (P = .000) in the WB-EMS group compared to CG. WB-EMS effects on bone are less pronounced than previously reported effects on muscle mass. However, for subjects unable or unwilling to perform intense exercise programs, WB-EMS may be an option for maintaining BMD at the LS. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"643520"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/643520","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33139847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50

Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype. 1型糖尿病和骨质疏松:从分子途径到骨骼表型。

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-03-22 DOI: 10.1155/2015/174186

Tayyab S Khan, Lisa-Ann Fraser

{"title":"Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype.","authors":"Tayyab S Khan, Lisa-Ann Fraser","doi":"10.1155/2015/174186","DOIUrl":"https://doi.org/10.1155/2015/174186","url":null,"abstract":"The link between type 1 diabetes mellitus (DM1) and osteoporosis, identified decades ago, has gained attention in recent years. While a number of cellular mechanisms have been postulated to mediate this association, it is now established that defects in osteoblast differentiation and activity are the main culprits underlying bone fragility in DM1. Other contributing factors include an accumulation of advanced glycation end products (AGEs) and the development of diabetes complications (such as neuropathy and hypoglycemia), which cause further decline in bone mineral density (BMD), worsening geometric properties within bone, and increased fall risk. As a result, patients with DM1 have a 6.9-fold increased incidence of hip fracture compared to controls. Despite this increased fracture risk, bone fragility remains an underappreciated complication of DM1 and is not addressed in most diabetes guidelines. There is also a lack of data regarding the efficacy of therapeutic strategies to treat osteoporosis in this patient population. Together, our current understanding of bone fragility in DM1 calls for an update of diabetes guidelines, better screening tools, and further research into the use of therapeutic strategies in this patient population. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"174186"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/174186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33217528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 74

Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study. 长期接受低剂量糖皮质激素治疗的自身免疫性疾病患者，口服钙二醇比补充胆骨化醇更有效达到足够的25(OH)D水平:一项“现实生活”研究

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-06-01 DOI: 10.1155/2015/729451

Miguel Ortego-Jurado, José-Luis Callejas-Rubio, Raquel Ríos-Fernández, Juan González-Moreno, Amanda Rocío González Ramírez, Miguel A González-Gay, Norberto Ortego-Centeno

{"title":"Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A \"Real-Life\" Study.","authors":"Miguel Ortego-Jurado, José-Luis Callejas-Rubio, Raquel Ríos-Fernández, Juan González-Moreno, Amanda Rocío González Ramírez, Miguel A González-Gay, Norberto Ortego-Centeno","doi":"10.1155/2015/729451","DOIUrl":"https://doi.org/10.1155/2015/729451","url":null,"abstract":"Glucocorticoids (GCs) are the cornerstone of the therapy in many autoimmune and inflammatory diseases. However, it is well known that their use is a double edged sword, as their beneficial effects are associated almost universally with unwanted effects, as, for example glucocorticoid-induced osteoporosis (GIO). Over the last years, several clinical practice guidelines emphasize the need of preventing bone mass loss and reduce the incidence of fractures associated with GC use. Calcium and vitamin D supplementation, as adjunctive therapy, are included in all the practice guidelines. However, no standard vitamin D dose has been established. Several studies with postmenopausal women show that maintaining the levels above 30-33 ng/mL help improve the response to bisphosphonates. It is unknown if the response is the same in GIO, but in the clinical practice the levels are maintained at around the same values. In this study we demonstrate that patients with autoimmune diseases, undergoing glucocorticoid therapy, often present suboptimal 25(OH)D levels. Patients with higher body mass index and those receiving higher doses of glucocorticoids are at increased risk of having lower levels of 25(OH)D. In these patients, calcidiol supplementations are more effective than cholecalciferol to reach adequate 25(OH)D levels. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"729451"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/729451","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33432247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

The Impact of Fracture Incidence on Health Related Quality of Life among Community-Based Postmenopausal Women. 骨折发生率对社区绝经后妇女健康相关生活质量的影响

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-07-30 DOI: 10.1155/2015/717914

A L Barcenilla-Wong, J S Chen, M J Cross, L M March

{"title":"The Impact of Fracture Incidence on Health Related Quality of Life among Community-Based Postmenopausal Women.","authors":"A L Barcenilla-Wong, J S Chen, M J Cross, L M March","doi":"10.1155/2015/717914","DOIUrl":"https://doi.org/10.1155/2015/717914","url":null,"abstract":"This prospective study aimed to examine the impact of fracture incidence on health-related quality of life (HRQOL) among postmenopausal women. Study subjects were Australian female community-dwellers in the Global Longitudinal Study of Osteoporosis in Women (GLOW). Self-administered questionnaires were collected annually from 2007 to 2010. Outcomes were the Medical Outcomes Study Short Form-36 (SF-36 physical function (SF36PFS) and vitality (SF36VS) scores), European Quality of Life (EQ-5D), and self-reported general health (GH) of excellent/good. Questionnaires were divided into prior to, the 1st, the 2nd, and the 3rd year after incident fracture assessments. Generalized linear models with generalised estimating equations (GEE) were employed for the analysis. The 2,872 participants (age: median 65; interquartile range 60-73 years) provided a total of 10,436 assessments including 266, 165 and 76 assessments for the 1st, the 2nd, and the 3rd year after incident fracture, respectively. Multivariate adjustments showed reductions in HRQOL measures peaking at the 1st year for SF36VS (coefficient -3.0; 95% CI: -5.1, -0.8) and EQ-5D (coefficient -0.03; 95% CI: -0.06, -0.00) and at the 2nd year for SF36PFS (coefficient -3.0; 95% CI: -5.6, -0.5) and GH (odds ratio 0.92; 95% CI: 0.70, 1.19). Fracture incidence reduced HRQOL including vitality and physical function among relatively young, healthy postmenopausal women and the reduction in European Quality of Life measure was clinically important. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"717914"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/717914","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34007596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Associations of polyunsaturated Fatty Acid intake with bone mineral density in postmenopausal women. 绝经后妇女多不饱和脂肪酸摄入与骨密度的关系。

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-02-17 DOI: 10.1155/2015/737521

Margaret Harris, Vanessa Farrell, Linda Houtkooper, Scott Going, Timothy Lohman

{"title":"Associations of polyunsaturated Fatty Acid intake with bone mineral density in postmenopausal women.","authors":"Margaret Harris, Vanessa Farrell, Linda Houtkooper, Scott Going, Timothy Lohman","doi":"10.1155/2015/737521","DOIUrl":"https://doi.org/10.1155/2015/737521","url":null,"abstract":"A secondary analysis of cross-sectional data was analyzed from 6 cohorts (Fall 1995-Fall 1997) of postmenopausal women (n = 266; 56.6 ± 4.7 years) participating in the Bone Estrogen Strength Training (BEST) study (a 12-month, block-randomized, clinical trial). Bone mineral density (BMD) was measured at femur neck and trochanter, lumbar spine (L2-L4), and total body BMD using dual-energy X-ray absorptiometry (DXA). Mean dietary polyunsaturated fatty acids (PUFAs) intakes were assessed using 8 days of diet records. Multiple linear regression was used to examine associations between dietary PUFAs and BMD. Covariates included in the models were total energy intake, body weight at year 1, years after menopause, exercise, use of hormone therapy (HT), total calcium, and total iron intakes. In the total sample, lumbar spine and total body BMD had significant negative associations with dietary PUFA intake at P < 0.05. In the non-HT group, no significant associations between dietary PUFA intake and BMD were seen. In the HT group, significant inverse associations with dietary PUFA intake were seen in the spine, total body, and Ward's triangle BMD, suggesting that HT may influence PUFA associations with BMD. This study is registered with clinicaltrials.gov, identifier: NCT00000399. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"737521"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/737521","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33139848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13